TABLE 3.
Activities of compounds 16h and 16l on HIV-1 laboratory strains (AD8 and NL4.3) and on tier 2 and 3 pseudovirusesa
| Compound | IC50 (mean ± SD) (μM) for: |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AD8 | NL4.3 | Pseudoviruses |
||||||||||
| QH0692.42 | SC422661.8 | PVO.4 | TRO.11 | AC10.0.29 | RHPA4259.7 | REJO4541.67 | TRJO4551.58 | WITO4160.33 | CAAN5342.A2 | |||
| 16h | 0.6 ± 0.3 | 0.75 ± 0.3 | 2.9 ± 0.3 | 1.5 ± 0.2 | 1.5 ± 0.4 | 7.7 ± 1.3 | 1 ± 0.3 | >10 | 1.5 ± 0.4 | 3.9 ± 0.2 | 3.9 ± 0.6 | 5.6 ± 0.3 |
| 16l | 0.8 ± 0.2 | 1 ± 0.3 | 4.1 ± 1.3 | 4.1 ± 1.3 | 1.3 ± 0.3 | 8.7 ± 1.4 | 1 ± 0.4 | >10 | 1.5 ± 0.5 | 3.3 ± 0.2 | 5 ± 0.1 | 5.6 ± 1.3 |
a
The IC50 values in μM (±SD) of dolutegravir on laboratory strains was 4 ± 3 nM; the IC50 of maraviroc on pseudoviruses was 19 ± 5 nM IC50. The experiments were repeated three times in triplicate.